x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012912
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human TMEM41B protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TMEM41B |
| UniProt No. | Q5BJD5 |
| Gene ID | 440026 |
| Gene Description | TMEM41B was discovered as a target of splicing dysfunction induced by loss of spinal motor neuron protein, a feature of spinal muscular atrophy, resulting in motor circuit defects. Loss of TMEM41B in mice results in embryonic lethality. TMEM41B is a transmembrane protein that resides at the endoplasmic reticulum and is found at contact sites between the ER and mitochondria. Independent CRISPR screens identified TMEM41B as a novel regulator of autophagy being structurally and functionally related to VMP1. Loss of TMEM41B inhibited autophagosome formation and autophagic flux. Furthermore, depletion of TMEM41B led to an accumulation of lipid droplets, indicating a role in lipid mobilization and utilization of fatty acids. TMEM41B also appeared in screens identifying it as an essential host protein for infection of flaviviruses and coronaviruses, including SARS-CoV-2. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
